David P. King - 20 May 2026 Form 4 Insider Report for Privia Health Group, Inc. (PRVA)

Reporting relationship: Director
Issuer ticker: PRVA
Reported as of: 20 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 May 2026, 08:24:37 UTC
Prior SEC filing: 23 May 2025
Next SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Anita Beth Adams, as attorney-in-fact

Key filing fact

David P. King filed Form 4 for Privia Health Group, Inc. (PRVA) on 22 May 2026.

Key facts

This page summarizes David P. King's Form 4 filing for Privia Health Group, Inc. (PRVA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 May 2026, 08:24.

Change

Previous filing in this sequence was filed on 23 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001275654 Primary reporting owner

KING DAVID P

Relationship: Director
Address: PRIVIA HEALTH GROUP, INC., 950 N. GLEBE RD., SUITE 700., ARLINGTON
Signature: /s/ Anita Beth Adams, as attorney-in-fact
Signature date: 22 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PRVA transaction

Common Stock, $0.01 par value per share

Award

Transaction value
Shares: +8,463
Change %: +20%
Price: $0.000000^*
Shares after: 50,775
Date: 20 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On May 20, 2026, the reporting person received 8,463 restricted stock units under the Issuer's 2021 Omnibus Incentive Plan. The restricted stock units will vest on the earlier of (i) the day immediately preceding the Company's 2027 annual meeting of stockholders and (ii) the first anniversary of the date of the grant.